{"Symbol": "PBMD", "AssetType": "Common Stock", "Name": "Prima Biomed Ltd", "Description": "Immutep Limited engages in the research, development, and commercialization of medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its core technologies are based on the lymphocyte activation gene-3 (LAG-3) immune control mechanism, which plays a vital role in the regulation of the T cell immune response. The company's lead product candidate is IMP321, a recombinant protein, which is in Phase IIb clinical trials in metastatic breast cancer when used as a chemoimmunotherapy, as well as in Phase I clinical trials in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody for immunosuppression in autoimmune diseases; IMP701, a LAG-3 antagonist antibody for immunostimulation to treat cancer; and IMP761, a LAG-3 agonist antibody for immunosuppression in autoimmune diseases. Immutep Limited is also developing CVac, an autologous dendritic cell therapy, which has completed Phase IIb clinical trials for ovarian cancer. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Other", "Industry": "Other", "Address": "None", "FullTimeEmployees": "0", "FiscalYearEnd": "None", "LatestQuarter": "None", "MarketCapitalization": "38959796", "EBITDA": "-6240000", "PERatio": "None", "PEGRatio": "0", "BookValue": "1", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.4", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "0", "ReturnOnEquityTTM": "0", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "0", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "7.09", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "0", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "None", "52WeekHigh": "None", "52WeekLow": "None", "50DayMovingAverage": "0", "200DayMovingAverage": "0", "SharesOutstanding": "0", "SharesFloat": "0", "SharesShort": "0", "SharesShortPriorMonth": "0", "ShortRatio": "0", "ShortPercentOutstanding": "0", "ShortPercentFloat": "0", "PercentInsiders": "0", "PercentInstitutions": "0", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}